v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Consolidated Statements of Operations

Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations, regularly reviewed by the Company’s CODM, include salaries and clinical trials expenses and presented below.

 

   Three months ended 
   March 31 
   2026   2025 
         
Operating expenses:        
Salaries and related expenses, other than share-based compensation   1,773    1,977 
Clinical trials   95    3,626 
Stock based compensation   (1,928)   659 
Depreciation expenses   
-
    236 
Insurance   843      
Other segment items (*)   513    1,258 
Total Operating expenses   1,296    7,756 

 

(*)Other segment items include all remaining costs necessary to operate the Company’s business, which primarily include external professional services, rent, insurance and other administrative expenses, and are presented net of grants received
Schedule of Consolidated Balance Sheets

The Company’s Property and equipment, as well as the Company’s operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:

 

   As of
March 31,
2026		   As of
December 31,
2025		 
         
Israel   
-
    5,791 
United States   
           -
    4,119 
Total   
-
    9,910